Publications by authors named "Nozar Azarnia"

Claim this Profile
V
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Aziz Nazha, Mikkael A Sekeres, Rami Komrokji, David P Steensma, Hagop Kantarjian, Nozar Azarnia

Blood Cancer J· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Maria R Baer, Mikkael A Sekeres, Nozar Azarnia

Lancet Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Heinz-Josef Lenz, Eric Van Cutsem, Shirin Khambata-Ford, Robert J Mayer, Philip Gold, Nozar Azarnia

J Clin Oncol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Gerald Batist, Lyndsay Harris, Nozar Azarnia, Lily Waiyee Lee, Pascual Daza-Ramirez

Anticancer Drugs· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
James A Bonner, Paul M Harari, Jordi Giralt, Nozar Azarnia, Dong M Shin

N Engl J Med· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Roy S Herbst, Matthew Arquette, Dong M Shin, Karel Dicke, Everett E Vokes, Nozar Azarnia

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.
Lyndsay Harris, Gerald Batist, Robert Belt, Douglas Rovira, Rudolph Navari, Nozar Azarnia

Cancer· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis